Moberg Pharma intends to distribute and separately list BupiZenge[®] (BUPI)
The Board of Directors of Moberg Pharma AB (OMX: MOB) today announces its intention to distribute the operations of BupiZenge[®] (BUPI) to the shareholders of Moberg Pharma by distributing 90 percent of the shares in a subsidiary (name to be changed to OncoZenge AB) through a so-called Lex ASEA distribution, and convenes an extraordinary general meeting to resolve accordingly. The business consists of developing the BUPI project under the brand name BupiZenge[®] for treatment of oral mucositis. Moberg Pharma estimates the capital requirement to take BupiZenge[®] through phase 3 at SEK 60